Active Ingredient History
Corifungin refers to the sodium salt of amphotericin B. Although amphotericin B has become the primary drug of choice for treating primary amoebic meningoencephalitis, its use is associated with multiple side effects, including use-limiting renal toxicity. Initial reports for the in vivo efficacy of corifungin in a mouse model of primary amoebic meningoencephalitis showed activity superior to that of amphotericin B at equivalent dosing. Chemically, corifungin is the sodium salt of amphotericin B with excellent aqueous solubility. The increased solubility of corifungin is likely to account for the described increase in activity. Acea Biotech is developing corifungin for the treatment of fungal infections and amebic diseases. Acea has completed of host of animal studies on corifungin setting the stage to take the drug into the clinic. U.S. FDA has approved orphan drug status for corifungin for the treatment of primary amebic meningoencephalitis. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Blastomycosis (approved 1992)
Coccidioidomycosis (approved 1992)
Acquired Immunodeficiency Syndrome (Phase 3)
Allogeneic Cells (Phase 2)
Antifungal Agents (Phase 4)
Aspergillosis, Allergic Bronchopulmonary (Phase 2/Phase 3)
Blastomycosis (Phase 4)
Burns (Phase 4)
Candida (Phase 4)
Candidemia (Phase 4)
Candidiasis (Phase 4)
Candidiasis, Chronic Mucocutaneous (Phase 2)
Candidiasis, Invasive (Phase 4)
Candidiasis, Oral (Phase 2)
Candidiasis, Vulvovaginal (Phase 3)
Colorectal Neoplasms (Phase 4)
Cryptococcosis (Phase 4)
Cryptococcus (Phase 1/Phase 2)
Cystic Fibrosis (Phase 1)
Esophageal Neoplasms (Phase 3)
Febrile Neutropenia (Phase 4)
Fever (Phase 3)
Fuchs' Endothelial Dystrophy (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 3)
Hematopoietic Stem Cell Transplantation (Phase 2)
Histoplasmosis (Phase 3)
HIV (Phase 2)
HIV Infections (Phase 3)
Immunologic Deficiency Syndromes (Phase 3)
Immunosuppression Therapy (Phase 3)
Infections ()
Invasive Fungal Infections (Phase 3)
Invasive Pulmonary Aspergillosis (Phase 4)
Leishmania (Phase 2)
Leishmaniasis (Phase 2)
Leishmaniasis, Cutaneous (Phase 4)
Leishmaniasis, Mucocutaneous (Phase 2/Phase 3)
Leukemia (Phase 4)
Leukemia, Myeloid, Acute (Phase 2)
Liver Diseases (Phase 4)
Liver Transplantation (Phase 4)
Lung Diseases (Phase 3)
Lung Transplantation (Phase 3)
Lymphoma (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Meningitis (Phase 2)
Meningoencephalitis (Phase 2)
Mucormycosis ()
Multiple Myeloma (Phase 3)
Mycoses (Phase 4)
Mycosis Fungoides (Phase 4)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Naegleria ()
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 3)
Neutropenia (Phase 3)
Obesity, Morbid (Phase 4)
Onychomycosis (Phase 4)
Sepsis (Phase 4)
Sinusitis (Phase 3)
Therapeutic Equivalency (Phase 1)
Vaginosis, Bacterial (Phase 3)
Vulvovaginitis (Phase 2)
Zygomycosis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
